Combinatorial Cancer Immunotherapies

被引：87

作者：

Hellmann, Matthew D. ^{[1
,2
]}

Friedman, Claire F. ^{[1
,2
]}

Wolchok, Jedd D. ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

来源：

TUMOR IMMUNOLOGY | 2016年 / 130卷

关键词：

REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; DOUBLET CHEMOTHERAPY; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; PD-1; BLOCKADE; DOUBLE-BLIND; DILATED CARDIOMYOPATHY; NIVOLUMAB ANTI-PD-1; BIOLOGICAL APPROACH;

D O I：

10.1016/bs.ai.2015.12.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T cell checkpoint blockade therapies are revolutionizing the treatment of patients with cancer. Highlighted by the recent success of PD-1 plus CTLA-4 blockade in patients with melanomas, synergistic immunotherapy combinations of modalities represent an important opportunity to improve responses and outcomes for patients. We review the rationale and experience with T cell checkpoint blockade in combination with targeting of other coinhibitory or costimulatory checkpoints, immunomodulatory molecules in the tumor microenvironment, and other anticancer modalities such as vaccines, chemotherapy, and radiation.

引用

页码：251 / 277

页数：27

共 171 条

[1] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].

Agata, Y ;

Kawasaki, A ;

Nishimura, H ;

Ishida, Y ;

Tsubata, T ;

Yagita, H ;

Honjo, T .

INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772

[2] OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand [J].

AlShamkhani, A ;

Birkeland, ML ;

Puklavec, M ;

Brown, MH ;

James, W ;

Barclay, AN .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) :1695-1699

[3] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[5] Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. [J].

Antonia, Scott Joseph ;

Goldberg, Sarah B. ;

Balmanoukian, Ani Sarkis ;

Sanborn, Rachel E. ;

Steele, Keith ;

Narwal, Rajesh ;

Robbins, Paul B. ;

Gu, Yu ;

Karakunnel, Joyson Joseph ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[6] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). [J].

Antonia, Scott Joseph ;

Brahmer, Julie R. ;

Gettinger, Scott N. ;

Chow, Laura Quan Man ;

Juergens, Rosalyn A. ;

Shepherd, Frances A. ;

Laurie, Scott Andrew ;

Gerber, David E. ;

Goldman, Jonathan Wade ;

Shen, Yun ;

Harbison, Christopher ;

Alaparthy, Suresh ;

Chen, Allen C. ;

Borghaei, Hossein ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[7] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. [J].

Antonia, Scott Joseph ;

Gettinger, Scott N. ;

Chow, Laura Quan Man ;

Juergens, Rosalyn A. ;

Borghaei, Hossein ;

Shen, Yun ;

Harbison, Christopher ;

Chen, Allen C. ;

Ready, Neal ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[8]

Antonia SJ, 2015, ASCO M, V33, P7503, DOI DOI 10.1200/JC0.2015.33.15_

[9]

Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO

[10]

2-4

← 1 2 3 4 5 6 7 8 9 10 →